What we do


RhabdoTec developed with its XU-platform technology a novel biotechnological method capable of producing novel pharmaceutical agents und derivatives in a cost efficient and fast manner. The procedure allows the specific programming of microorganisms – of nonribosomal peptide synthetases, respectively – for the production of peptides, e.g. antimicrobial, anticarcinogenic and immunosuppressant agents. Nonribosomal peptide synthetases in combination with the technology developed by the team are especially suitable for an efficient synthesis of complex cyclic peptides containing unusual building blocks – these are chemically not fabricable or require a tremendous effort which makes it economically unreasonable.



Who we are

The BioTech StartUp RhabdoTec consists of the three scientists Dipl.-Bioinf. Kenan Bozhüyük, M. Sc. Mol. Biotech. Florian Fleischhacker and Dipl.-Bioinf. Darko Kresovic who have completed their Ph.Ds at the Goethe-University Frankfurt am Main at the institute for molecular biosciences in the working group of Prof. Dr. Helge Bode. The team is completed with the industrial engineer Dipl.-Ing. Felix Wersich.

RhabdoTec placed first at the Innovationsforum 2016 organized by Handelsblatt and was rewarded with 10.000 € price money.



More information about the award (in German):